- Home
- LEU vs ORIC Comparison
LEU vs ORIC Comparison
Compare LEU & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEU
- ORIC
- Stock Information
- Founded
- LEU 1998
- ORIC 2014
- Country
- LEU United States
- ORIC United States
- Employees
- LEU N/A
- ORIC N/A
- Industry
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- LEU Industrials
- ORIC Health Care
- Exchange
- LEU Nasdaq
- ORIC Nasdaq
- Market Cap
- LEU 1.3B
- ORIC 735.3M
- IPO Year
- LEU 1998
- ORIC 2020
- Fundamental
- Price
- LEU $83.63
- ORIC $11.08
- Analyst Decision
- LEU Buy
- ORIC Strong Buy
- Analyst Count
- LEU 2
- ORIC 9
- Target Price
- LEU $92.00
- ORIC $18.75
- AVG Volume (30 Days)
- LEU 726.1K
- ORIC 825.1K
- Earning Date
- LEU 02-06-2025
- ORIC 03-10-2025
- Dividend Yield
- LEU N/A
- ORIC N/A
- EPS Growth
- LEU 50.42
- ORIC N/A
- EPS
- LEU 4.70
- ORIC N/A
- Revenue
- LEU $394,000,000.00
- ORIC N/A
- Revenue This Year
- LEU $25.25
- ORIC N/A
- Revenue Next Year
- LEU $5.68
- ORIC N/A
- P/E Ratio
- LEU $17.17
- ORIC N/A
- Revenue Growth
- LEU 14.94
- ORIC N/A
- 52 Week Low
- LEU $33.51
- ORIC $6.33
- 52 Week High
- LEU $118.36
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- LEU 50.41
- ORIC 59.70
- Support Level
- LEU $77.01
- ORIC $9.95
- Resistance Level
- LEU $85.60
- ORIC $12.01
- Average True Range (ATR)
- LEU 5.90
- ORIC 0.86
- MACD
- LEU -0.36
- ORIC 0.04
- Stochastic Oscillator
- LEU 28.71
- ORIC 64.50
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.